PCSK9 and aortic stenosis: As PCSK9 inhibitors reduce LDL-cholesterol by 50 to 60% and Lp(a) by 20 to 30% [38–40], this raises the possibility that pharmacologic lipid-lowering therapy could offer a means to prevent or slow AS progression.